Skip to main content
. 2017 Oct 12;33(6):225–236. doi: 10.1177/8755122517735656

Table 3.

ORs (95% CIs) of In-Hospital Mortality Following TBI Comparing Statin Users and Nonusers by Individual Months Prior to TBI.

Unadjusted
Use in Months Prior to TBI
−1 −2 −3 −4 −5 −6
Any statin use 0.96 (0.92, 1.00) 0.94 (0.82, 1.08) 1.07 (0.90, 1.26) 1.15 (0.95, 1.39) 0.92 (0.72, 1.16) 0.95 (0.73, 1.22)
 Atorvastatin 1.00 (0.94, 1.07) 0.89 (0.71, 1.11) 1.12 (0.71, 1.11) 1.26 (0.97, 1.62) 0.99 (0.74, 1.34) 0.64 (0.44, 0.93)
 Fluvastatin 0.74 (0.50, 1.09) 0.39 (0.05, 2.84) 0.69 (1.17, 2.91) 0.69 (0.17, 2.91) 0.50 (0.07, 3.69) NAa
 Lovastatin 1.03 (0.91, 1.16) 0.89 (0.55, 1.44) 1.81 (1.15, 2.84) 0.92 (0.48, 1.75) 1.40 (0.82, 2.40) 1.31 (0.72, 2.38)
 Pravastatin 1.04 (0.92, 1.18) 0.87 (0.53, 1.43) 0.73 (0.37, 1.43) 1.03 (0.54, 1.98) 0.63 (0.28, 1.43) 1.22 (0.61, 2.43)
 Rosuvastatin 0.83 (0.71, 0.97) 1.44 (0.98, 2.10) 0.46 (0.21, 0.98) 0.79 (0.40, 1.56) 1.21 (0.68, 2.14) 0.51 (0.21, 1.26)
 Simvastatin 0.93 (0.88, 0.99) 0.93 (0.77, 1.14) 1.00 (0.78, 1.27) 1.08 (0.82, 1.42) 0.71 (0.50, 1.01) 1.11 (0.81, 1.51)
Adjustedb
Use in Months Prior to TBI
−1 −2 −3 −4 −5 −6
Any statin use 0.89 (0.84, 0.94) 0.84 (0.71, 0.98) 0.98 (0.81, 1.18) 0.98 (0.79, 1.23) 0.86 (0.66, 1.12) 0.81 (0.61, 1.08)
 Atorvastatin 0.91 (0.84, 0.99) 0.74 (0.57, 0.96) 0.18 (0.90, 1.53) 1.12 (0.83, 1.50) 0.98 (0.70, 1.36) 0.60 (0.40, 0.91)
 Fluvastatin 0.74 (0.47, 1.15) 0.63 (0.08, 4.67) 0.95 (0.22, 4.04) 1.06 (0.25, 4.52) 0.58 (0.08, 4.40) N/Aa
 Lovastatin 1.01 (0.87, 1.16) 0.72 (0.40, 1.28) 1.17 (0.65, 2.09) 1.01 (0.49, 2.09) 1.43 (0.80, 2.56) 1.03 (0.50, 2.14)
 Pravastatin 0.97 (0.84, 1.12) 0.83 (0.48, 1.44) 0.79 (0.39, 1.62) 0.73 (0.32, 1.67) 0.36 (0.12, 1.07) 1.00 (0.43, 2.34)
 Rosuvastatin 0.74 (0.62, 0.89) 1.54 (1.00, 2.37) 0.54 (0.24, 1.23) 0.88 (0.42, 1.85) 1.10 (0.55, 2.21) 0.68 (0.27, 1.71)
 Simvastatin 0.86 (0.80, 0.92) 0.86 (0.69, 1.08) 0.89 (0.68, 1.18) 0.91 (0.66, 1.25) 0.68 (0.46, 1.02) 0.94 (0.65, 1.34)

Abbreviations: OR, odds ratio; CI, confidence interval; TBI, traumatic brain injury; CHF, congestive heart failure; AMI, acute myocardial infarction; IHD, ischemic heart disease; VHD, valvular heart disease; ADRD, Alzheimer’s disease and related dementias; SNF, skilled nursing facility; SRRi, independent survival risk ratio.

a

Estimate too small and unreliable.

b

Adjusted for demographic characteristics (age, sex, race, income, region); medications (antiplatelets, anticoagulants, beta-blockers, other statins); cardiovascular disease (CHF, AMI, IHD, VHD, hyperlipidemia, hypertension, prior stroke); diabetes; Alzheimer’s disease and related dementia; count of CCW chronic conditions excluding cardiovascular conditions (hypertension, hyperlipidemia, ischemic heart disease, congestive heart failure, acute myocardial infarction, valvular heard disease) and diabetes and ADRD; SNF stay in month prior to TBI; injury severity (SRRi, length of hospital stay); provider and hospital characteristics per 100 000 population (physicians, hospitals, hospitals with trauma services, hospitals with neurological services, beds).